Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neo-adjuvant Pembrolizumab in Vulvar Squamous Cell Carcinoma: a Clinical Proof-of-concept Study

NCT05761132 is registered in ClinicalTrials.gov with Leiden University Medical Center as lead sponsor.

NCT NCT05761132
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05761132 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neo-adjuvant Pembrolizumab in Vulvar Squamous Cell Carcinoma: a Clinical Proof-of-concept Study
Lead sponsor
Leiden University Medical Center
Phase
Phase 2
Overall status
Unknown status
Start date
April 1, 2023
Completion date
February 1, 2025
Enrollment
40 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

squamous cell cancer, vulva cancer, vulva neoplasm